Combination lipid therapy in type 2 diabetes mellitus

Bibliography

• Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524
   PubMedGoogle Scholar
• Haffner SM, Lehto S, Ronnemaa T, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HAW, ; for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8
   PubMed Web of Science ®Google Scholar
• Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005;31:429-39
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49
   PubMed Web of Science ®Google Scholar
• Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009;23:681-5
   PubMed Web of Science ®Google Scholar
• Duvillard L, Pont F, Florentin E, Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000;30:685-94
   PubMed Web of Science ®Google Scholar
• FIELD study investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005;4:13
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Howard BV, Dc Robbins, Sievers ML, LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the strong heart study. Arterioscler Thromb Vasc Biol 2000;20:830-5
   PubMed Web of Science ®Google Scholar
• West KM, Ahuja MM, Bennett PH, The role of circulating glucose and triglyceride concentrations and their interactions with other ‘risk factors’ as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983;6:361-9
   PubMed Web of Science ®Google Scholar
• Fontbonne A, Eschwege E, Cambien F, Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4
   PubMed Web of Science ®Google Scholar
• Janka HU. Five-year incidence of major macrovascular complications in diabetes mellitus. Horm Metab Res Suppl 1985;15:15-19
   PubMedGoogle Scholar
• Lehto S, Ronnemaa T, Haffner SM, Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9
   PubMed Web of Science ®Google Scholar
• Scott R, O'Brien R, Fulcher G, Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8
   PubMed Web of Science ®Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM, Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-19
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R, Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
   PubMed Web of Science ®Google Scholar
• Costa J, Borges M, David C, Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, ; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Deedwania P, Barter P, Carmena R, ; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, ; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, ; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, ; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-dyslipidemia/lipid management. Diabetes Care 2010;S30-2
   Google Scholar
• Polonsky TS, Davidson MH. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol 2008;101:27B-35B
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC. Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes. Atheroscler Suppl 2010;11:61-4
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Fenofibrate: metabolic and pleitropic effects. Curr Vasc Pharmacol 2005;3:87-98
   PubMedGoogle Scholar
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10
   PubMed Web of Science ®Google Scholar
• Vakkilainen J, Steiner G, Ansquer JC, ; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604
   PubMed Web of Science ®Google Scholar
• Robins SJ, Rubins HB, Faas FH, ; Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-17
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-4
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ. ‘If it ain’t broke, don't fix it': a commentary on the positive-negative results of the ACCORD lipid study. Cardiovasc Diabetol 2010;9:24
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
   PubMed Web of Science ®Google Scholar
• Verges B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr Med Res Opin 2005;21(Suppl 1):S29-40
   Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, ; Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews D, Charbonnel B, Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, ; Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000;22:1395-409
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17
   PubMed Web of Science ®Google Scholar
• Winkler K, Friedrich I, Baumstark MW, Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002;2:143-8
   Google Scholar
• Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48:2477-81
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Dole JF, Patwardhan R, ; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Gomis R, Squatrito S, Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction – results from PROactive (PROactive 05). J Am Coll Cardiol 2007;49:1772-80
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Bays HE, Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-7
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute (NHLBI). Niacin Plus Statin to Prevent Vascular Events. Available from: www.clinicaltrials.gov/ct/show/NCT00120289. [Last accessed 6 February 2011]
   Google Scholar
• University of Oxford. HPS2-THRIVE: Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events. Available from: www.controlled-trials.com/ISRCTN29503772, [Last accessed 21 January 2011]
   Google Scholar
• Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009;5:901-8
   PubMedGoogle Scholar
• Kashyap ML, McGovern ME, Berra K, Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-8
   PubMed Web of Science ®Google Scholar
• Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998;21:494-500
   PubMed Web of Science ®Google Scholar
• Belalcazar LM, Reboussin DM, Haffner SM, ; Look AHEAD (Action for Health in Diabetes) Obesity, Inflammation, and Thrombosis Research Group. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010;33:197-9
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). Effects of omega-3 fatty acids on lipids. 2004, Evidence Report/Technology Assessment: Number 89. Available from: http://www.ahrq.gov/clinic/epcsums/o3lipidsum.htm [Last accessed 28 January 2011]
   Google Scholar
• Hooper L, Thompson RL, Harrison RA, Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004:CD003177
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, ; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lutjohann D, Kodal A, Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8
   PubMed Web of Science ®Google Scholar